Chen, Y., Liu, L., Cheng, Y., Araneta, A., Castano, N., Gomez, J., Ajmera, A., Ye, H., Runcie, K., McHugh, D. J., Offit, K., Paller, C. J., Haas, N. B., Franklin, R. A., Pili, R., Javier-Desloges, J., Kane, C. J., Seibert, T. M., Bagrodia, A., McKay, R. R. (2025). A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.5_suppl.tps430